Skip to main content
An official website of the United States government

Cabozantinib-S-Malate

Placeholder slot
 (KA-boh-ZAN-tih-nib ... MA-layt)

Cabozantinib-s-malate works by blocking proteins that signal cancer cells to divide. It also blocks proteins that signal the growth of new blood vessels that supply oxygen and nutrients needed for tumor growth. Blocking these signals keeps cancer cells from growing and spreading to other parts of the body. Cabozantinib-s-malate is a type of targeted therapy drug called a kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily).

US Brand Name(s)
Cabometyx
Cometriq
FDA Approved
Yes

FDA label information for this drug is available at DailyMed.

Use in Cancer

Cabozantinib-s-malate is approved to treat:

Cabozantinib-s-malate is also being studied in the treatment of other types of cancer.

More About Cabozantinib-S-Malate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Cabozantinib-S-Malate (for thyroid cancer) and Cabozantinib-S-Malate (for renal cell carcinoma) - Lay language summaries of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

Targeted Therapy to Treat Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Cabozantinib S-malate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated:
Email